Trial reportArthritis research & therapy2009
Alterations in peripheral blood memory B cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor.
Trial report in Arthritis research & therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 57 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 125 citations in OpenAlex.
- Activated Peripheral Blood B Cells in Rheumatoid Arthritis and Their Relationship to Anti-Tumor Necrosis Factor Treatment and Response: A Randomized Clinical Trial of the Effects of Anti-Tumor Necrosis Factor on B Cells.Arthritis & rheumatology (Hoboken, N.J.) · 2022Trial
- Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.PloS one · 2015Trial
- B cells contribute to heterogeneity of IL-17 producing cells in rheumatoid arthritis and healthy controls.PloS one · 2013Trial
- Exploratory analysis of early changes in peripheral immune cell proportions and clinical response following methotrexate and biologic treatment in rheumatoid arthritis.Journal of rheumatic diseases · 2026Article
- Comparative Analysis of Circulating and Synovial Immune Cells in Early Untreated Rheumatoid Arthritis and Their Relationship With Molecular Pathology and Disease Outcomes.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- PD-L1International journal of molecular sciences · 2025Article
- Immunophenotyping of Patients With Rheumatoid Arthritis Reveals Difference in CD27Mediators of inflammation · 2025Article
- JAK inhibitors attenuate hyperactivation of nonswitched memory B cells in rheumatoid arthritis patients in remission.Arthritis research & therapy · 2024Article
- Effect of the immune cells and plasma metabolites on rheumatoid arthritis: a mediated mendelian randomization study.Frontiers in endocrinology · 2024Article
- Aberrant B-cell activation and B-cell subpopulations in rheumatoid arthritis: analysis by clinical activity, autoantibody seropositivity, and treatment.Clinical and experimental immunology · 2023Article
- Human B-cell subset identification and changes in inflammatory diseases.Clinical and experimental immunology · 2022Review
- B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?Frontiers in medicine · 2022Review
- Double-negative (DN) B cells: an under-recognized effector memory B cell subset in autoimmunity.Clinical and experimental immunology · 2021Review
- Review
- B cells from Patients with Rheumatoid Arthritis Show Conserved CD39-Mediated Regulatory Function and increased CD39 Expression After Positive Response to Therapy.Journal of molecular biology · 2021Article
- The role of B cells in heart failure and implications for future immunomodulatory treatment strategies.ESC heart failure · 2020Review
- Whole Transcriptome Analysis Reveals Heterogeneity in B Cell Memory Populations in Patients With Juvenile Idiopathic Arthritis-Associated Uveitis.Frontiers in immunology · 2020Article
- Infliximab therapy together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia.BMC cancer · 2019Article
- Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis.ACS chemical biology · 2019Article
- Vasculitis in a Child With the Hyper-IgM Variant of Ataxia-Telangiectasia.Frontiers in pediatrics · 2019Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
Abstract
introductionDisturbances in peripheral blood memory B cell subpopulations have been observed in various autoimmune diseases, but have not been fully delineated in rheumatoid arthritis (RA). Additionally, the possible role of tumour necrosis factor (TNF) in regulating changes in specific peripheral blood memory B cell subsets in RA is still unclear.
methodsThe frequency and distribution of B cell subsets in the peripheral blood and synovial membrane of active RA patients with long-standing disease have been analysed. Additionally, the possible role of TNF in causing disturbances in memory B cell subsets in RA patients was assessed in a clinical trial with the specific TNF-neutralising antibody, infliximab.
resultsRA patients, independent of disease duration, have a significantly lower frequency of peripheral blood pre-switch IgD+CD27+ memory B cells than healthy individuals, whereas post-switch IgD-CD27+ accumulate with increased disease duration. Notably, both pre-switch IgD+CD27+ and post-switch IgD-CD27+ memory B cells accumulate in the synovial membrane of RA patients. Finally, anti-TNF therapy increased the frequency of pre-switch IgD+CD27 memory B cells in the peripheral blood.
conclusionsThe data suggest that decreases in peripheral blood IgD+CD27+ pre-switch memory B cells in RA reflect their accumulation in the synovial tissue. Moreover, the significant increase in the peripheral blood pre-switch memory B cells in patients who underwent specific TNF-blockade with infliximab indicates that trafficking of memory B cells into inflamed tissue in RA patients is regulated by TNF and can be corrected by neutralising TNF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.